
#JPM23: BeiGene CEO John Oyler on the company's big ambitions
BeiGene CEO John Oyler and Endpoints News Executive Editor Drew Armstrong spoke one-on-one about where the drugmaker is headed in its quest to become a diversified multinational, and what it will take to get there. This transcript has been edited for brevity and clarity.
Drew Armstrong:
I am joined today by BeiGene CEO John Oyler. By way of introduction, John and I met about a little over three years ago for the first time in Beijing, when I was doing some reporting. I got to travel around the country and I had this huge notebook full of reporting on interesting things that his company was doing and some of the other companies were doing over there. And I came back to the states ready to write a great magazine story about BeiGene and about innovation that was happening globally. And then I think we all know what happened about a week and a half after I returned, in January of 2020. And unfortunately that work never saw the light of day.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.